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isoproterenol; sodium reabsorption; rolipram; PDE4; hypertension THE THICK ASCENDING LIMB of the loop of Henle (THAL) reabsorbs ϳ30% of the filtered NaCl in a process mediated by the apical Na-K-2Cl cotransporter NKCC2 (19, 24, 43, 47) . To mediate NaCl reabsorption from the tubular lumen, NKCC2 must be present at the apical membrane of THALs. Several hormones such as arginine vasopressin (AVP), parathyroid hormone, glucagon, and ␤-adrenergic agonists stimulate THAL NaCl absorption by increasing cAMP (cyclic adenosine monophosphate) production (7, 17, 22, 24, 25, 31, 43, 47) . We (3, 43) have previously shown that AVP stimulates NKCC2-dependent NaCl reabsorption by increasing trafficking of NKCC2 to the apical membrane in rat THALs via cAMP. However, it is not known whether other hormones or neurotransmitters that stimulate cAMP enhance surface NKCC2 in the THAL.
Enhanced renal nerve activity stimulates NaCl absorption by the THAL (7, 15, 24, 49) . Various adrenergic receptors including ␤-1 and ␤-2 (58) are expressed in rat THALs. In isolated THALs, stimulation of ␤-adrenergic receptors enhances intracellular cAMP production by adenylyl cyclase (16) and stimulates Cl absorption (7, 41, 48) . Chronic stimulation of ␤-adrenergic receptors enhances NKCC2 expression (56) , and this is likely to contribute to long-term control of blood pressure. However, stimulation of ␤-adrenergic receptors enhance NaCl absorption within 20 to 30 min, suggesting an acute effect on NKCC2 activity. We (12) have reported that cAMP acutely stimulates NKCC2 trafficking via protein kinase A (PKA). However, it is not known whether stimulation of ␤-adrenergic receptors enhances apical surface expression of NKCC2 and whether this is mediated by cAMP and PKA.
␤-Adrenergic receptor stimulation increases intracellular cAMP in THALs (7, 18) . In most cells, cAMP is rapidly degraded by various cAMP-specific phosphodiesterases (PDEs) that modulate the magnitude of cAMP actions (3, 12, 44, 46) . There are 11 different types of PDEs of which 8 are considered cAMP specific (29) . PDEs differ on their structure, localization, cellular expression, inhibitor sensitivity (9, 10), and affinity for cAMP (9, 10) . Some of them are expressed in the kidney (3, 9, 46, 59) . In THALs, only PDE1 and PDE2 have been confirmed to be expressed (3, 9, 32) . However, in collecting ducts, PDE-dependent cAMP activity is known to be contributed primarily by PDE4 (38, 57) . In other cells, PDE4 is primarily responsible for decreasing cAMP generated by ␤-adrenergic stimulation (6, 60) . Thus we hypothesized that ␤-adrenergic receptor stimulation enhances surface NKCC2 expression in rat THALs and this is blunted by PDE4.
MATERIALS AND METHODS
Suspensions of medullary THALs. Male Sprague Dawley rats were anesthetized with ketamine (100 mg/kg bw ip) and xylazine (20 mg/kg bw ip). Medullary THAL suspensions were prepared according to the method described previously (3, 12, 23, 43) . In brief, kidneys were perfused via the aorta with perfusion solution (in mM: 130 NaCl, 2.5 NaH 2PO4 3Ϫ , 4.0 KCl, 1.2 MgSO4, 6 L-alanine, 1.0 disodium citrate, 5.5 glucose, 2.0 calcium lactate, and 10 HEPES, pH 7.4) containing 0.1% collagenase (Sigma, St. Louis, MO) and 100 U heparin. The outer medulla was dissected, minced, and digested in collagenase to obtain THAL suspensions.
Surface biotinylation of THAL suspensions. Cell surface proteins were biotinylated as described in detail previously (3, 12, 23, 43) . THAL suspensions were equilibrated at 37°C for 10 min followed by treatment with the corresponding drugs for 30 min and oxygenated every 5 min with 100% O 2 with gentle mixing. When an inhibitor was used, it was added at the time of equilibration so that blockade was complete. Then, the suspensions were cooled rapidly to 4°C, washed twice with chilled perfusion solution, and centrifuged at 100 g for 2 min. THAL suspensions were incubated 30 min at 4°C in biotinylation solution (in mM: 10 HEPES, 130 NaCl, 2 MgSO 4, 1 CaCl2, and 5.5 glucose, pH: 7.8 -8.0) containing 0.9 mg/ml NHS-SS-biotin (Thermo Scientific) in a rocker. After biotinylation, tubules were washed three times at 4°C: once with perfusion solution and twice with perfusion solution containing 100 mM glycine to remove the excess of NHS-SS-biotin. THAL suspensions were centrifuged (100 g) and lysed in buffer containing the following (in mM): 150 NaCl, 50 HEPES, and 5 EDTA, plus 2% Triton X-100, 0.2% SDS, and protease inhibitors (10 g/ml aprotinin, 5 g/ml leupeptin, 4 mmol/l benzamidine, 5 g/ml chymostatin, and 5 g/ml pepstatin A; Sigma), pH 7.5.
For measurement of surface NKCC2, 80 g of biotinylated THAL proteins from each experimental sample were incubated in two rounds with streptavidin-coated agarose beads. Surface proteins were extracted from the beads by boiling in 50 l SDS-loading buffer containing 50 M DL-dithiothreitol and 5% ␤-mercaptoethanol as described in detail in our previous studies (3, 4, 12, 23, 43) . For total NKCC2 measurement, a one-tenth fraction of the supernatant (8 g of total protein), containing intracellular nonbiotinylated proteins, was loaded in the same gels with surface fractions recovered from the beads. NKCC2 was detected by Western blot. Optical densities from surface and intracellular NKCC2 bands were used to calculate total NKCC2 and the ratio of surface to total NKCC2. Given the small percentage of NKCC2 at the surface (3-5%; Ref. 43) , changes in the surface fraction do not result in detectable changes in the intracellular fraction. Day-to-day variation in surface biotinylation experiments in vehicle-treated samples (controls) was 8.1% across data sets. Thus the variability of surface NKCC2 in control THALs was acceptable.
Western blot analysis. THAL lysates were resolved by SDS polyacrylamide gel electrophoresis in 6.5% gels and transferred to Hybond PVDF membranes (GE Health Care). The PVDF membrane was incubated for 60 min in blocking buffer containing 50 mM Tris, 150 mM NaCl, 3% BSA, and 0.1% Tween-20. Then, 1:1,000 dilution of anti-NKCC2 raised in chicken was incubated overnight at 4°C in blocking buffer. This antibody was raised against a synthetic peptide corresponding to amino acids 33-55 of rat NKCC2 (3, 43) . Next, the membrane was incubated with anti chicken secondary antibody (1: 10,000 conjugated with horseradish peroxidase; Thermo Fisher Scientific; Ref. 43) . Bands were developed with ECL solution (GE Health Care). Surface NKCC2 and total NKCC2 were calculated by densitometry.
To assure that the surface fraction does not contain intracellular protein, we measured GAPDH in the surface and intracellular fraction in each experiment. For GAPDH immunoblotting, PVDF membranes were blocked with a mixture of 2.5% BSA and 2.5% milk for 60 min. We used primary monoclonal anti-GAPDH (Chemicon) at 1:60,000 for 120 min at room temperature in 3% BSA. Finally, anti-mouse secondary antibody conjugated to horseradish peroxidase (GE Health Care) was used at a 1:12,000 for 60 min at room temperature in 3% BSA.
To determine which PDE4 isoforms are expressed in THALs, we used 15-25 g of total THAL lysate, resolved them by SDS-PAGE (7% gels), and transferred to Hy-bond PVDF membranes. PVDF membranes were incubated for 60 min in blocking buffer containing 50 mM Tris, 150 mM NaCl, 3% BSA, and 0.1% Tween-20. Then, the membranes were incubated with previously characterized isotypespecific pan-antibodies (Fabgennix): PDE4A (PD4-112AP), PDE4B (PD4-231), PDE4C (PD4-301), or PDE4D (PD4-401). For all antibodies except PDE4C, we used 1:1,000 for primary and secondary antibodies. For PDE4C, we used 1:2,000 primary antibody and 1:5,000 for the secondary antibody.
Intracellular cAMP measurements. Intracellular cAMP was determined by RIA after sample acetylation (Biomedical Technologies) as described earlier (3). In brief, THAL suspensions were aliquoted and equilibrated in physiological perfusion solution (mentioned above) at 37°C for 10 min. Then, vehicle, isoproterenol, or rolipram was added to the bath and incubated for 10 min. The reaction was stopped by addition of 1.5 ml of chilled perfusion solution containing the general PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX; 1 mM). To prevent endogenous nitric oxide (NO) production and decrease the variability of baseline cAMP, the NO synthase inhibitor N -L-arginine methyl ester was included in the solution. THALs were then washed by centrifugation (160 g) at 4°C, lysed in chilled solution containing 50% methanol/distilled water, and stored at Ϫ80°C for 1 h. Lysates were spun at 16,000 g, and the supernatant was recovered and stored at Ϫ80°C. The pellet was used for determination of total protein (in duplicate) by colorimetric commercial assay (Thermo Fisher Scientific). Samples were dried overnight on a Savant centrifuge dryer, the dried pellet was reconstituted in 240 l of assay buffer, and cAMP was determined by RIA. Internal standards and recoveries were run with each experiment. Intracellular cAMP content was expressed as femtomoles per micrograms of protein.
Statistics. Results are expressed as means Ϯ SE. Differences between means were evaluated with one-way ANOVA, using Bonferroni adjustment for multiple comparisons. P Ͻ 0.05 was considered significant.
RESULTS
Effect of ␤-adrenergic receptor stimulation on surface NKCC2 expression in rat THALs. First, we studied whether ␤-adrenergic receptor stimulation with the agonist isoproterenol (Iso) enhances surface NKCC2 in THALs. Rat THAL suspensions obtained from the same animal were divided into four aliquots and treated with vehicle (control) or isoproterenol to reach a final concentration of 0.2, 0.5, and 1.0 M. After treatment (30 min), we measured surface and total NKCC2 in THALs by surface biotinylation as described in MATERIALS AND METHODS. Data were normalized to surface NKCC2 in controls that was set to 100%. We found that isoproterenol at 0.2 M did not affect surface NKCC2 (102 Ϯ 3%), whereas at 0.5 and 1.0 M it enhanced surface NKCC2 to 117 Ϯ 1 and 129 Ϯ 5%, respectively ( Fig. 1 ; n ϭ 6). We also measured total NKCC2 expression and found no effect of Iso on total NKCC2 levels (control: 100, 0.2 M Iso: 108 Ϯ 3%, 0.5 M Iso: 115 Ϯ 13%, and 1 M Iso: 109 Ϯ 15%). GAPDH was not detected in the surface fraction while observed in the total/intracellular fractions. These data indicate that ␤-adrenergic receptor stimulation increases steady-state surface NKCC2 in THALs.
Effect of phosphodiesterase inhibition on ␤-adrenergic receptor-stimulated surface NKCC2 expression in rat THALs. ␤-Adrenergic receptor stimulation increases cAMP production in THALs (18) . However, cAMP produced by ␤-adrenergic receptor stimulation is quickly degraded by phosphodiesterases, which may decrease the effect of isoproterenol. To test this, we used the nonspecific phosphodiesterase inhibitor IBMX (0.5 mM). THAL suspensions were divided into four aliquots and treated with vehicle, IBMX, 1 M Iso, or IBMX ϩ 1 M Iso. IBMX alone did not change surface NKCC2, whereas it potentiated the stimulatory effect of Isoproterenol (control: 100%, IBMX: 109 Ϯ 5%, Iso: 129 Ϯ 6%, and IBMX ϩ Iso: 151 Ϯ 8%; Fig. 2 ). Inhibition of PDEs with IBMX enhanced the effect of isoproterenol on surface NKCC2 by ϳ75% (P Ͻ 0.02 vs. Iso). No significant change in total NKCC2 was observed in this group of experiments (control: 100%, IBMX: 100 Ϯ 2%, Iso: 94 Ϯ 3%, and IBMX ϩ Iso: 95 Ϯ 2%). GAPDH was not present in the surface fraction. These data indicate that the stimulatory effect of isoproterenol on surface NKCC2 expression is blunted by the action of phosphodiesterases.
Effect of ␤-adrenergic receptor antagonism on isoproterenolstimulated surface NKCC2 expression in rat THALs. Because PDE inhibition with IBMX enhanced the stimulatory effect of isoproterenol, we used this combination in subsequent blockade experiments. To test whether the effect of isoproterenol is solely mediated by ␤-adrenergic receptor stimulation, we used the ␤-adrenergic receptor antagonist propranolol (Pro, 10 M). THAL suspensions were separated into four aliquots and treated with vehicle, Pro, IBMX ϩ Iso (1 M), and Pro ϩ IBMX ϩ Iso. Propranolol did not affect surface NKCC2, but it completely blocked the stimulatory effect of IBMX ϩ Iso on surface NKCC2 (control: 100%, Pro: 107 Ϯ 3%, IBMXϩ Iso: 144 Ϯ 8%, and Pro ϩ IBMX ϩ Iso: 104 Ϯ 4%; P Ͻ 0.05 vs. IBMX ϩ Iso; Fig. 3 ). No significant changes in total NKCC2 were observed in any group (control: 100%, Pro: 93 Ϯ 4%, IBMX ϩ Iso: 103 Ϯ 10%, and Pro ϩ IBMX ϩ Iso: 92 Ϯ 6%). GAPDH was not detected in the surface fraction. These data indicate that isoproterenol stimulates NKCC2 trafficking by acting on ␤-adrenergic receptors.
Effect of PDE4 inhibition on isoproterenol-stimulated surface NKCC2 expression in rat THALs. During the dose-response effect to isoproterenol, we observed that 0.2 M did not increase surface NKCC2 (Fig. 1) . Therefore, we used this lower concentration to test whether selective PDE4 inhibition with rolipram enhances the effect of ␤-adrenergic stimulation on surface NKCC2 expression in THALs. THAL suspensions were divided into four aliquots and treated with either vehicle, 20 M rolipram, 0.2 M Iso, or 20 M rolipram ϩ 0.2 M Iso for 30 min. We found that 0.2 M Iso enhanced surface NKCC2 only when PDE4 was inhibited by rolipram (control: 100%, 0.2 M Iso: 100 Ϯ 5%, 20 M rolipram: 106 Ϯ 6%, and rolipram ϩ Iso: 126 Ϯ 8%; P Ͻ 0.05 vs. Iso; Fig. 4, A and  B) . No significant changes were observed in total NKCC2 expression (control: 100%, 20 M rolipram: 105 Ϯ 2%, 0.2 M Iso: 99 Ϯ 5%, and rolipram ϩ Iso: 102 Ϯ 3%). GAPDH was not observed in the surface fraction. These data indicate that ␤-adrenergic receptor-mediated stimulation of NKCC2 trafficking is blunted by the action of PDE4. Western blot analysis of PDE4 isoforms present in rat THALs. Pharmacological blockade of PDE4 by rolipram indicates that PDE4 is present in THALs, yet the expression of PDE4 has not been studied in THALs. There are four PDE4 families: PDE4A/B/C/D, each with many splice variants. Using antibodies directed to conserved regions in the different PDE4 families, we studied which isoforms were detected in THALs by Western blot. Splice variants for each family were identified based on their different molecular mass. A pan-PDE4A antibody recognized three predominant bands at ϳ 76, 102, and 109 kDa corresponding to isoforms PDE4A1 (76 kDa), PDEAX (102 kDa), and PDE4A5 (109 kDa; Fig. 6 ) (20, 34) . Two of these bands were also present in brain homogenate (76 and 102 kDa). A PDE4B pan antibody detected one predominant band at ϳ85 kDa and two less dense bands at 60 and 68 kDa. They might correspond to PDE4B4 (85 kDa; Ref.
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52), PDE4B5 (58 -60 kDa), and a short form of PDE4B2 (68 kDa; Fig. 6) (13, 52) . A single band at 86 kDa was predominant in brain homogenate. The PDE4C pan antibody detected a predominant band at ϳ 64 kDa and less dense bands at 80 and 94 kDa. The 64-kDa band may correspond to a short PDE4C variant (⌬54; Ref. 42) and is similar to that reported in lung and other tissues (61) , while the 80-kDa band may correspond to PDE4C2 (Fig. 6) (26, 30, 42, 45) . The PDE4C antibody reacted strongly with recombinant GST-PDE4C (75 kDa). Finally, a PDE4D pan-antibody detected bands at ϳ68, 78, 90, and 100 kDa corresponding to PDE4D2/6 (68 kDa), PDE4D1 (78 kDa), PDE4D3/8/9 (90 kDa), and PDE4D5/7 (102 kDa; Fig. 6 ) (51, 57) . In brain homogenate, three bands were observed at 72, 78, and 102 kDa. These data indicate that multiple PDE4 isoforms and variants are expressed in THALs.
DISCUSSION
␤-Adrenergic receptor stimulation enhances NaCl reabsorption by the THAL. However, the molecular mechanisms by which this occurs remain poorly explored. In the current study, we have addressed the role of ␤-adrenergic stimulation on trafficking of NKCC2 to the cell surface and the signaling pathway involved. We found that stimulation of ␤-adrenergic receptors enhanced cAMP and surface NKCC2 levels and that PKA was required for this stimulatory effect. We also found that inhibition of PDE4 enhanced the stimulatory effect of ␤-adrenergic receptors on intracellular cAMP and NKCC2 trafficking to the surface in THALs. Taken together, these data indicate that ␤-adrenergic receptor stimulation enhances NKCC2 trafficking in THALs via cAMP and that PDE4 blunts this effect.
In the present study, we demonstrated that acute stimulation of ␤-adrenergic receptors in THALs increases NKCC2 trafficking to the plasma membrane. We also found that this occurs within a time frame (20 -30 min) where total NKCC2 expression did not change. We (4) previously showed that trafficking of NKCC2 to the cell surface is essential to acutely stimulate NaCl absorption by the THAL, independently of changes on total NKCC2 expression. Thus we think this mechanism provides a way to quickly enhance salt reabsorption during heightened norepinephrine/epinephrine release by renal nerves. In addition to the acute effect on NKCC2, a previous report by Sonalker et al. (55) showed that chronic infusion of norepinephrine (NE) increases the total expression of NKCC2 in rats. Thus our data and that of others suggest that NKCC2 stimulation in the THAL is an essential component of catecholamine-induced antinatriuresis.
Isoproterenol stimulates both, ␤ 1 -and ␤ 2 -adrenergic receptors, which are expressed in the THAL (18, 39) . Previous evidence indicates that ␤ 1 -receptors are the main contributors to adrenergic stimulation of cAMP in THALs (18). While we have used isoproterenol to stimulate ␤-receptors, ␣-adrenergic receptors are also expressed in the THAL (39, 40) . However, ␣ 2 -receptor activation inhibits NaCl transport in the THAL (48) by increasing NO production (48, 49) , which directly inhibits NKCC2 trafficking and activity. In light of these observations, it is unlikely that ␣-adrenergic receptors play a role in isoproterenol-induced stimulation of NKCC2 trafficking. To confirm the role of ␤-adrenergic receptors on NKCC2 trafficking, we used the antagonist propranolol. We observed that blockade of ␤-adrenergic receptors with propranolol in THALs completely prevented the stimulation induced by isoproterenol on surface NKCC2 expression even in the presence of the nonspecific phosphodiesterase inhibitor IBMX. Propranolol or IBMX alone did not affect surface NKCC2 (Figs. 2 and  3) , suggesting that ␤-adrenergic receptors are inactive in THAL suspensions in the absence of agonists. This is most likely due to washout of endogenous catecholamines during the preparation of THAL suspensions. These data confirm the stimulatory role of ␤-adrenergic receptors on NKCC2 trafficking in the THAL. The effect of isoproterenol on surface NKCC2 is comparable to the effect of higher concentrations of NE on net Cl reabsorption. Plato (48) ing ␣ 2 -receptors, whereas at 10 M NE increased net Cl transport by 20%. In agreement with our data, Baum (8) found that isoproterenol (1 M) stimulated Cl reabsorption in rat medullary THALs by 20 -25%. These data suggest that maximal ␤-adrenergic receptor stimulation is required to stimulate NKCC2 surface expression. It has long been recognized that stimulation of ␤-adrenergic receptors enhances intracellular cAMP in THALs. However, cAMP levels are regulated by stimulated production and also by degradation via phosphodiesterases. We found that the nonspecific phosphodiesterase inhibitor IBMX enhanced the stimulatory effect of isoproterenol on surface NKCC2. These data suggest that cAMP-phosphodiesterases blunt the action of ␤-adrenergic receptors on NKCC2 trafficking. We (12) previously found that general phosphodiesterase inhibition enhanced the effect of vasopressin on NKCC2 trafficking to a maximum of 52%. Because vasopressin also enhances NKCC2 activity via cAMP, it is possible that cAMP phosphodiesterases are part of a negative feedback regulatory mechanism that limits the stimulation of NKCC2 and NaCl transport in the THAL.
Most cells express multiple phosphodiesterases. The specific subset of phosphodiesterases expressed in THALs is not known. To our knowledge, only the expression of PDE1 and PDE2 has been reported at the protein level in THALs (3, 9, 32) . However, PDE4 is expressed in most cells and is known to blunt ␤-adrenergic signaling in other cells (1, 6, 11, 60 ). Thus we focused on PDE4. In the present study, we used the PDE4 inhibitor rolipram (28) to differentiate the effects of PDE4 from other cAMP-phosphodiesterases that are inhibited by IBMX. We tested whether rolipram (20 M) potentiated the effect of isoproterenol on surface NKCC2. From our initial concentration-response curve, we selected 0.2 M isoproterenol, the highest concentration that did not stimulate surface NKCC2. At this concentration, isoproterenol only enhanced surface NKCC2 in the presence of 20 M rolipram. Taken together, these data indicate that PDE4 blunts the stimulatory effect of ␤-adrenergic receptor stimulation on NKCC2 trafficking in THALs. Studies (1, 6, 11, 60) in other cells also point to a role of PDE4 on limiting ␤-adrenergic receptor signaling. To examine the role of PDE4 in ␤-adrenergic receptor-stimulated intracellular cAMP, we measured cAMP levels in THALs. As expected, a nonstimulatory concentration of isoproterenol or rolipram did not increase cAMP. However, a combination of both drugs significantly increased intracellular cAMP. These observations indicate that mild stimulation of ␤-adrenergic receptors with isoproterenol enhances cAMP production, which is immediately degraded by PDE4. Surface NKCC2 was also enhanced by PDE4 inhibition under these conditions. Thus our data indicate that ␤-adrenergic stimulation produces cAMP that enhances NKCC2 trafficking, whereas PDE4 decreases the magnitude of this stimulatory response by immediately degrading cAMP.
There are 4 genes encoding PDE4 A/B/C/D generating Ͼ13 PDE4 isoforms that result from alternative splicing (27) . We used antibodies recognizing conserved but distinct regions of the four PDE4 families to explore their expression in THALs. Given the large number of splice variants and the tissue specificity of each variant there is some controversy on the molecular mass for each PDE4. In general, all PDE4 isoforms run at a higher molecular mass than predicted by their sequence (20, 30, 37, 50, 51, 52) in SDS-PAGE. However, the splice variants for each family exhibit different molecular mass allowing their identification. Using this approach, we report that at least twelve PDE4 variants of the four families (PDE4A/B/ C/D) are detected in THAL lysates. This is not surprising as most cell types express PDE4A/B/C/D and multiple variants (20, 30, 37, 50, 51, 52) . The PDE4 isoforms PDE4D and to a lesser extent PDE4B seem to be the main contributors limiting ␤-adrenergic signaling in other cells (5, 60) . PDE4D seems to be responsible for inhibiting vasopressin action in the collecting duct (57) . The relative contribution of the twelve different PDE4 isoforms in THAL physiology is unknown. In the future, it could be important to determine the specific PDE4 isoform that blunts ␤-adrenergic signaling and vasopressin signaling in the THAL.
We (12) previously found that cAMP enhances NKCC2 exocytosis in part by stimulating PKA. To begin exploring the signaling pathway by which ␤-adrenergic receptors stimulate NKCC2 trafficking we used H-89, a PKA inhibitor. We observed that H-89 completely prevented the stimulatory effect of ␤-adrenergic stimulation on surface NKCC2 expression. These data are in agreement with our previous report (12) showing that vasopressin stimulates surface NKCC2 by activating PKA. In addition to vasopressin and ␤-adrenergic stimulation, dopamine has been shown to stimulate NaCl transport in the THAL by PKA (2) . How the same second messenger (cAMP) participates in different signaling pathways still requires further investigation. It is possible that cAMP is produced by the same pool of adenylyl cyclase following receptor stimulation, or that cAMP converges into PKA to stimulate trafficking, or that the various receptors stimulate different compartments of cAMP production and signaling. In most cells studied, compartmentalization provides an efficient mechanism to limit cAMP signal propagation, which in most cases includes a signaling complex with a unique phosphodiesterase and PKA anchoring (12) .
Renal interstitial release of norepinephrine from renal sympathetic nerves is a potent source of catecholamines reaching the kidney. Renal nerve stimulation enhances Na and Cl absorption by the loop of Henle as indicated by in vivo micropuncture studies (15) . Increased renal sympathetic nerve activity has long been associated with hypertension in humans and animals (14, 21, 35, 36, 54) . In addition, animal models of salt sensitive hypertension like the Dahl rat exhibit higher renal sympathetic nerve activity (53) and abnormally enhanced NaCl absorption by the THAL (23, 33) . Our observations provide a new mechanism by which catecholamines enhance NaCl absorption via stimulation of NKCC2 trafficking in the THAL. This mechanism may be enhanced in salt-sensitive hypertension.
In summary, we conclude that ␤-adrenergic receptor stimulation enhances NKCC2 trafficking to the apical membrane of THALs by increasing intracellular cAMP levels and subsequent activation of PKA. The stimulatory response is blunted by PDE4, which degrades cAMP. In this way, PDE4 provides a possible mechanism for restricting ␤-adrenergic signaling on NKCC2 trafficking in the THAL.
